MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from
underwritten offering of...
$124,315K
Proceeds from issuance of
common shares upon...
$1,707K
Net cash provided by
(used in) financing...
$123,715K
Canceled cashflow
$2,307K
Net increase
(decrease) in cash and cash...
$52,889K
Canceled cashflow
$70,826K
Term loan principal
payments
$1,500K
Underwritten offering
issuance costs paid
$716K
Deferred offering costs
paid
$91K
Maturities of marketable
securities
$33,487K
Stock-based compensation
expense
$4,256K
Deferred revenue
$437K
Accounts payable
$326K
(gain) loss from
changes in fair value on...
$107K
Non-cash lease expense
$65K
Depreciation expense
$63K
Accounts receivable
-$60K
Non-cash interest
expense
$16K
Other assets
-$1K
Net cash used in
investing activities
-$46,753K
Net cash used in
operating activities
-$24,046K
Effect of changes in
exchange rate on cash and...
-$27K
Canceled cashflow
$33,487K
Canceled cashflow
$5,331K
Purchases of marketable
securities
$80,214K
Net loss
-$22,253K
Accrued expenses and
other current...
-$3,843K
Purchase of property and
equipment
$26K
Prepaid expenses and
other current assets
$2,975K
Accretion of net
investment discounts
$306K
Back
Back
Cash Flow
BioAge Labs, Inc. (BIOA)
BioAge Labs, Inc. (BIOA)
source: myfinsight.com